Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2024-11-11 Director's Dealing
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically '장내매수' or open-market purchases) made by a director (Kim Hun-taek) of TiumBio. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2024-11-11 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for shareholder list closure due to a small-scale merger. It does not contain full financial statements or detailed merger terms, but rather serves as a formal notice of a corporate action (setting a record date). As it is a standard regulatory notification regarding corporate governance and shareholder rights that does not fit into specific categories like M&A (TAR) or Dividend (DIV), it is classified as a general regulatory filing.
2024-10-28 Korean
[첨부추가]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a merger (회사합병 결정) between TiumBio and Petraon. It details the merger ratio, valuation methods, external evaluation report, and the timeline for the merger process. This type of document is a formal announcement of a merger and acquisition (M&A) activity, which falls under the 'M&A Activity' category.
2024-10-28 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the acquisition of convertible bonds before maturity by the issuer (TiumBio). This type of disclosure, specifically detailing the repurchase of debt instruments (convertible bonds) by the company, falls under capital structure and financing updates. Given the specific nature of the transaction (debt repurchase), it is classified as a Capital/Financing Update.
2024-09-02 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for TiumBio, covering the period from January 1, 2024, to June 30, 2024. It contains detailed corporate information, financial data, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (혈우병 치료신약 TU7710의 유럽 임상 1b상 시험계획(IND) 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (TiumBio) regarding a material management decision, specifically the approval of a clinical trial (IND) for a new drug (TU7710). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2024-07-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.